Peptides for solubilizing protein aggregates and methods thereof

By identifying and using charged amphiphilic peptides to dissolve protein aggregates, combining DNA and viral vector technology, the problem of difficult protein aggregates in neurodegenerative diseases is solved, and the potential therapeutic effect on a variety of neurodegenerative diseases is achieved.

CN118900844APending Publication Date: 2024-11-05RJK BIOPHARMA LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380022570.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-17
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing methods have not yet effectively reversed progressive degeneration of neurons, resulting in neurodegenerative diseases that are considered incurable and lack treatments that can effectively dissolve pathogenic protein aggregates.

Method used

By identifying charged amphiphilic peptides (Champ regions) with specific amino acids and producing peptides composed of these regions that are contacted with protein aggregates to dissolve them, it is introduced into the cells in combination with DNA or RNA encoding and viral vector technology, Used to treat neurodegenerative diseases.

Benefits of technology

The dissolution of protein aggregates in a variety of neurodegenerative diseases has been achieved, showing potential therapeutic effects, which can reduce or eliminate disease symptoms, and show significant depolymerization effects in vivo and in vitro.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004999501600000131
    Figure BDA0004999501600000131
  • Figure BDA0004999501600000141
    Figure BDA0004999501600000141
  • Figure HDA0004999501610000011
    Figure HDA0004999501610000011
Patent Text Reader

Abstract

The present disclosure provides a method of producing a peptide capable of solubilizing protein aggregates. Also provided is a method of treating a neurodegenerative disease using such peptides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates generally to neurobiology and neurodegenerative diseases. In particular, the present invention relates to methods for producing peptides capable of solubilizing pathogenic protein aggregates and methods of using such peptides. Background Art

[0002] Protein aggregation is a common feature of many neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease. Protein aggregates in neurons, such as FUS in ALS, beta-amyloid in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and huntingtin in Huntington's disease, appear to be toxic, causing neuronal damage or death. In general, the extent of aggregation is proportional to the severity of the neurodegenerative disease.

[0003] Although the cause of protein aggregation in neurons is not fully understood, it appears that aggregation-prone proteins are often supersaturated in cells, i.e., the cellular concentration of the protein exceeds the thermodynamic solubility but is maintained in a metastable liquid-like state by buffering of heterotypic interactions. Disorders in the supersaturated metastable form lead to loss of protein solubility and cause protein aggregation.

[0004] Several attempts have been made to develop therapeutic agents for neurodegenerative diseases by inhibiting protein aggregation or dissolving pathogenic protein aggregates. For example, compounds capable of inhibiting protein aggregation have been disclosed in U.S. Patents 10435373, 9738635, 10889584, 9284309, 9527852 and 9790188. U.S. Patent 9845327 discloses inhibiting protein aggregation by promoting lysosomal activity. However, since there is still no known method to reverse the progressive degeneration of neurons, neurodegenerative diseases are considered incurable. Therefore, it is necessary to develop new compositions and methods to inhibit protein aggregation or dissolve protein aggregates in neurons. Summary of the invention

[0005] In one aspect, the present disclosure provides a method for producing peptides capable of dissolving protein aggregates. In certain embodiments, the method comprises: identifying a naturally occurring protein having a charged amphipathic (Champ) region of 40 to 100 amino acid residues, wherein (a) at least 30% of the amino acid residues in the Champ region are charged amino acid residues selected from Asp, Glu, Arg and Lys, wherein at least 80% of the charged amino acid residues are in the N-terminus or C-terminus of the Champ region, (b) 14% to 26% of the amino acid residues in the Champ region are hydrophobic amino acid residues selected from Phe, Cys, Leu, Val and Ile, and (c) at least 10% of the amino acid residues in the Champ region are polar amino acid residues selected from Ser, Asn, Thr, Gln, Tyr, Cys and His; and producing a peptide consisting of the Champ region. In certain embodiments, the method further comprises: contacting the peptide with a protein aggregate; and determining that the peptide dissolves the protein aggregate. In certain embodiments, the method further comprises mutating any of the charged amino acid residues in the peptide to a different charged amino acid residue.

[0006] In another aspect, the present disclosure provides a peptide produced according to the method disclosed herein.

[0007] In another aspect, the present disclosure provides a polynucleotide encoding a peptide disclosed herein. In certain embodiments, the polynucleotide is DNA or RNA.

[0008] In another aspect, the present disclosure provides a vector comprising a polynucleotide disclosed herein. In certain embodiments, the vector is a viral vector, such as an AAV vector.

[0009] In another aspect, the present disclosure provides a recombinant virus comprising a polynucleotide disclosed herein. In certain embodiments, the recombinant virus is AAV.

[0010] In another aspect, the present disclosure provides a host cell comprising a polynucleotide disclosed herein.

[0011] In another aspect, the present disclosure provides a pharmaceutical composition comprising: (1) a peptide disclosed herein, a polynucleotide disclosed herein, a vector disclosed herein, a recombinant virus disclosed herein, or a host cell disclosed herein; and (2) a pharmaceutically acceptable carrier.

[0012] In another aspect, the present disclosure provides a method for dissolving protein aggregates in cells. In certain embodiments, the method comprises introducing a peptide disclosed herein into the cells. In certain embodiments, the cells are neuronal cells. In certain embodiments, the cells are in vitro or in vivo.

[0013] In another aspect, the present disclosure provides a method for treating a neurodegenerative disease in a subject in need thereof. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition disclosed herein. In certain embodiments, the neurodegenerative disease is selected from the group consisting of frontotemporal dementia, amyotrophic lateral sclerosis, cortical basal gangliadegeneration, Lewy body dementia, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic granular disease, Alzheimer's disease, Parsons / dementia complex in the Kii Peninsula, progressive supranuclear palsy, and Pick's disease. In certain embodiments, the pharmaceutical composition is administered to the central nervous system. In certain embodiments, the pharmaceutical composition is administered by spinal injection, intrathecal injection, intracerebroventricular injection, intracerebral injection, or intrahippocampal injection. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The following drawings form part of this specification and are included in this specification to further illustrate certain aspects of the present disclosure. The present disclosure may be better understood by referring to one or more of these drawings in conjunction with the detailed description of specific embodiments presented herein.

[0015] Figure 1 The distribution of different types of amino acid residues in the peptide Champ-E having a depolymerizing effect is shown.

[0016] Figure 2 Shown are the sequences of a series of variant peptides derived from Champ-E.

[0017] Figure 3 Shown is Coomassie blue staining of Champ-E variants purified from recombinant E coli.

[0018] Figure 4 The effect of Champ-E variants in solubilizing G3BP1 aggregates is shown.

[0019] Figure 5 The role of Champ-E variants in solubilizing FDA is shown.

[0020] Figure 6 An experimental design for identifying depolymerizing peptides from eukaryotic cells is shown.

[0021] Figure 7 Depolymerization of PLPR3 peptides in eukaryotic cells is shown.

[0022] Figure 8 Depolymerization of the ATXN80S peptide in eukaryotic cells is shown.

[0023] Fig. 9 Depolymerization of the GRWD1 peptide in eukaryotic cells is shown.

[0024] Fig.10 Depolymerization of the TSYL2 peptide in eukaryotic cells is shown.

[0025] Fig.11 Depolymerization of the C19L2 peptide in eukaryotic cells is shown.

[0026] Fig.12 Depolymerization of ZNF326 peptide in eukaryotic cells is shown.

[0027] Fig.13 Depolymerization of the CACNA1F peptide in eukaryotic cells is shown.

[0028] Fig.14 Depolymerization of variant Champ6EK peptides in eukaryotic cells is shown.

[0029] Fig.15 Depolymerization of CHD3 peptide in eukaryotic cells is shown.

[0030] Fig.16 Depolymerization of variant CHD3(E2K) peptides in eukaryotic cells is shown.

[0031] Fig.17Depolymerization of the PELP1 peptide in vivo is shown.

[0032] Fig.18 The amino acid codes are shown. DETAILED DESCRIPTION

[0033] Before describing the present disclosure in more detail, it should be understood that the present disclosure is not limited to the particular embodiments described and therefore may of course vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting, as the scope of the present disclosure will be limited only by the appended claims.

[0034] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, preferred methods and materials are now described.

[0035] All publications and patents cited in this specification are incorporated herein by reference, just as each individual publication or patent is specifically and individually intended to be incorporated by reference and is incorporated herein by reference, so as to disclose and describe the methods and / or materials in conjunction with the cited publications. Reference to any publication is for its disclosure prior to the filing date, and should not be construed as an admission that the present disclosure is not entitled to antedate such publications by virtue of prior disclosure. Further, the publication dates provided may be different from the actual publication dates, which may need to be separately confirmed.

[0036] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features that can be readily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be performed in the order of events recited or in any other order that is logically possible.

[0037] definition

[0038] It should be understood that the above general description and the following detailed description are only exemplary and illustrative, and are not limitations of the claimed invention. In the present application, unless otherwise specifically stated, the use of the singular includes the plural. In the present disclosure, unless explicitly intended to refer only to alternatives or alternatives are mutually exclusive, the term "or" is used to mean "and / or". As used herein, "another" may mean at least a second or more. In addition, the use of the term "including" and other forms such as "includes" and "included" is not restrictive. In addition, unless otherwise specifically stated, terms such as "element" or "component" cover elements and components including a unit and elements and components including more than one subunit. In addition, the use of the term "portion" may include a portion or the entire portion of a portion.

[0039] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0040] As used herein, the term "administering" refers to providing a pharmaceutical agent or pharmaceutical composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0041] As used herein, the term "amino acid" refers to an organic compound containing amino (-NH2) and carboxyl (-COOH) functional groups and side chains unique to each amino acid. Amino acid names are also represented in this disclosure by standard single-letter or three-letter codes.

[0042] As used herein, a "cell" can be prokaryotic or eukaryotic. Prokaryotic cells include, for example, bacteria. Eukaryotic cells include, for example, fungi, plant cells, and animal cells. Preferably, the cells described herein are animal cells.Types of animal cells (e.g., mammalian cells or human cells) include, for example, cells from the nervous system or organs, for example, neurons, glial cells (e.g., astrocytes and oligodendrocytes), microglia, magnocellular neurosecretory cells, stellate cells, Boettcher cells, and pituitary cells (e.g., gonadotrophs, corticotrophs, thyrotrophs, somatotrophs, and lactotrophs); cells from the circulating / immune system or organs, for example, B cells, T cells (cytotoxic T cells, natural killer T cells, regulatory T cells, T helper cells), natural killer cells, granulocytes (e.g., basophils, eosinophils, neutrophils, and hypersegmented neutrophils); from the endocrine system or organs, for example, thyroid cells (e.g., thyroid epithelial cells, parafollicular cells), parathyroid cells (e.g., parathyroid chief cells, eosinophils), adrenal cells (e.g., chromaffin cells), and pineal cells (e.g., pinealocytes); from the respiratory system or organs, for example, lung cells (type I pneumocytes and type II pneumocytes), clara cells, goblet cells, alveolar macrophages; from the circulatory system or organs, for example, cardiomyocytes and pericytes; from the digestive system or organs, for example, gastric mucosal chief cells, parietal cells, goblet cells, Paneth cells, G cells, D cells, ECL cells, I cells, K cells, S cells, enteroendocrine cells, enterochromaffin cells, APUD cells, liver cells (liver cells) (e.g., hepatocytes and Kupffer cells); cells from the skin system or organs, for example, bone cells (e.g., osteoblasts, osteocytes and osteoclasts), tooth cells (e.g., cementoblasts and ameloblasts), cartilage cells (e.g., chondroblasts and chondrocytes), skin / hair cells (e.g., hair cells, keratinocytes and melanocytes (nevus cells), muscle cells (e.g., myocytes), adipocytes, fibroblasts and tendon cells; cells from the urinary system or organs (e.g., podocytes, juxtaglomerular cells, intraglomerular mesangial cells, extraglomerular mesangial cells, renal proximal brush border cells and macula densa cells); and cells from the reproductive system or organs (e.g., sperm, Sertoli cells, Leydig cells, eggs, oocytes).The cell can be a normal, healthy cell; or a diseased or unhealthy cell (e.g., a cancer cell). The mammalian cell can be a rodent cell, such as a mouse, rat, or hamster cell. The mammalian cell can be a lagomorph cell, such as a rabbit cell. The mammalian cell can also be a primate cell, such as a human cell.

[0043] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of an agent sufficient to prevent, treat, alleviate and / or ameliorate the symptoms and / or underlying causes of any condition or disease, or an amount of an agent sufficient to produce a desired effect on a cell. In one embodiment, a "therapeutically effective amount" refers to an amount sufficient to reduce or eliminate the symptoms of a disease. In another embodiment, a therapeutically effective amount is an amount sufficient to overcome the disease itself.

[0044] The term "host cell" means a cell that has been transformed or is capable of being transformed with a nucleic acid sequence and thereby expresses a desired protein. The term includes progeny of a parent cell, whether or not the progeny is identical to the original parent cell in morphology or genetic makeup, as long as the desired gene is present.

[0045] As used herein, the term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise indicated, a specific polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs and complementary sequences as well as sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see Batzer et al., Nucleic Acids Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0046] "Percentage (%) of sequence identity" with respect to an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in the candidate sequence that are identical to the amino acid (or nucleic acid) residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum number of identical amino acids (or nucleic acids). Conservative substitutions of amino acid residues may or may not be considered identical residues. Alignment for determining percent identity of amino acid (or nucleic acid) sequences can be achieved, for example, using publicly available tools such as BLASTN, BLASTp (available on the website of the US National Center for Biotechnology Information (NCBI), see also Altschul SF et al., J. Mol. Biol. 215:403-410 (1990); Stephen F et al., Nucleic Acids Research, 25:3389-3402 (1997)), ClustalW2 (available on the website of the European Bioinformatics Institute, see also Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin et al., Methods in Enzymology, 267:383-402 (1997); MA et al. Bioinformatics (Cambridge, England), 23(21):2947-8 (2007)) and ALIGN or Megalign (DNASTAR) software. Those skilled in the art can use the default parameters provided by the tools or can customize the parameters appropriately according to the needs of the comparison, for example, by selecting a suitable algorithm.

[0047] The term "polypeptide" or "protein" means a string of at least two amino acids interconnected by peptide bonds. Polypeptides and proteins may include moieties other than amino acids (e.g., may be glycosylated) and / or may be processed or modified in other ways. One of ordinary skill in the art will appreciate that a "polypeptide" or "protein" may be a complete polypeptide chain produced by a cell (with or without a signal sequence) or may be a functional portion thereof. One of ordinary skill in the art will further appreciate that a "polypeptide" or "protein" may sometimes include more than one polypeptide chain, for example, linked by one or more disulfide bonds or bound by other means. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of corresponding naturally occurring amino acids and polymers.

[0048] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient or solvent encapsulating material, etc. involved in carrying or transporting the subject compound from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; pH buffered solutions; polyesters, polycarbonates, and / or polyanhydrides; and other nontoxic, compatible substances employed in pharmaceutical formulations.

[0049] The term "protein aggregate" as used herein refers to the aggregation of proteins that occur inside or outside cells. In some embodiments, the protein is an intrinsic disordered protein or a misfolded protein. In some embodiments, aggregation occurs when the concentration of the protein exceeds the solubility of the protein. In some embodiments, the concentration of the protein exceeds the thermodynamic solubility, but the protein is maintained in a metastable liquid state by the buffering of heterotypic interactions. Disturbance of the metastable form of the protein can lead to loss of protein solubility and cause protein aggregation.

[0050] The term "recombinant" when used in reference to a polypeptide (e.g., an antibody, an antigen) or a polynucleotide refers to a polypeptide or polynucleotide produced by a recombinant method. A "recombinant polypeptide" includes any polypeptide expressed by a recombinant polynucleotide. A "recombinant polynucleotide" includes any polynucleotide that has been modified by the introduction of at least one exogenous (i.e., foreign, and generally heterologous) nucleotide or by altering at least one of the native nucleotide components of the polynucleotide, and need not include all coding sequences or regulatory elements naturally associated with coding sequences. A "recombinant vector" refers to a non-naturally occurring vector, including, for example, a vector comprising a recombinant polynucleotide sequence.

[0051] As used herein, the term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Humans include prenatal and postnatal forms. In many embodiments, the subject is a human. The subject can be a patient, which refers to a human being presented to a medical provider for diagnosis or treatment of a disease. The term "subject" is used interchangeably herein with "individual" or "patient". A subject may suffer from a disease or condition or be susceptible to a disease or condition, but may or may not exhibit symptoms of the disease or condition.

[0052] As used herein, "treating" or "treatment" of a condition includes preventing or alleviating the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, alleviating or ending symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or some combination thereof.

[0053] As used herein, "vector" refers to a nucleic acid molecule introduced into a host cell, thereby producing a transformed host cell. The vector may include a nucleic acid sequence that allows it to replicate in the host cell, such as an origin of replication. The vector may also include one or more therapeutic genes and / or optional marker genes and other genetic elements known in the art. The vector may transduce, transform or infect cells, thereby causing the cells to express non-cell-intrinsic nucleic acids and / or proteins. The vector optionally includes materials that help to achieve entry of nucleic acids into cells, such as viral particles, liposomes, protein coatings, etc.

[0054] Methods for producing aggregate-dissolving peptides

[0055] Protein aggregation is a biological phenomenon in which intrinsic disordered proteins or misfolded proteins aggregate (i.e., accumulate and gather together) in cells or outside cells. The protein structure is stabilized by non-covalent interactions and disulfide bonds between two cysteine ​​residues. Non-covalent interactions include ionic interactions and weak van der Waals interactions. Ionic interactions are formed between anions and cations, and form salt bridges that help stabilize proteins. Van der Waals interactions include non-polar interactions and polar interactions (i.e., hydrogen bonds, dipole-dipole bonds). These play an important role in the secondary structure of proteins, such as forming alpha helices or beta folds, and also play an important role in tertiary structures. The interactions between the amino acid residues in a particular protein are very important in the final structure of the protein.

[0056] When non-covalent interactions change, such as may occur with changes in the amino acid sequence, proteins are prone to misfolding or unfolding. In these cases, if the cell cannot help the protein refold or degrade the unfolded protein, the unfolded / misfolded protein may aggregate, where exposed hydrophobic parts of the protein may interact with other exposed hydrophobic patches of the protein. Three main types of protein aggregates can be formed: amorphous aggregates, oligomers, and amyloid fibrils. Misfolded protein aggregates are often associated with disease. For example, protein aggregates are associated with a variety of neurodegenerative diseases, including ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease, and prion diseases.

[0057] In one aspect, the present disclosure provides a method for identifying a polypeptide capable of dissolving protein aggregates. In certain embodiments, the method comprises: identifying a naturally occurring protein having a charged amphipathic (Champ) region of 40 to 100 amino acid residues, wherein (a) at least 30% of the amino acid residues in the Champ region are charged amino acid residues selected from Asp, Glu, Arg and Lys, wherein at least 80% of the charged amino acid residues are in the N-terminus or C-terminus of the Champ region, (b) 14% to 26% of the amino acid residues in the Champ region are hydrophobic amino acid residues selected from Phe, Cys, Leu, Val and Ile, and (c) at least 10% of the amino acid residues in the Champ region are polar amino acid residues selected from Ser, Asn, Thr, Gln, Tyr, Cys and His; and generating a peptide consisting of the Champ region.

[0058] In certain embodiments, the method further comprises: contacting the peptide with protein aggregates; and determining that the peptide dissolves the protein aggregates. In certain embodiments, the protein aggregates are FUS aggregates, TDP43 aggregates, TIA1 aggregates, and C9orf72 aggregates. In some embodiments, the peptide is capable of dissolving at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of the protein aggregates.

[0059] Variants of polypeptides can be produced by replacing amino acid residues in polypeptides so that variants have sequences with at least 90% identity to polypeptides, or sequences with 1, 2, 3, 4 or 5 amino acid residue differences with polypeptides. The generated variants can then be tested for their ability to dissolve protein aggregates. In some embodiments, the variants have improved ability to dissolve protein aggregates compared to the polypeptides from which the variants are derived. In certain embodiments, the method further comprises mutating any one of the charged amino acid residues in the peptides to different charged amino acid residues.

[0060] Compositions for solubilizing protein aggregates

[0061] In another aspect, the present disclosure provides a peptide capable of solubilizing protein aggregates. In some embodiments, the peptide is produced according to the methods disclosed herein.

[0062] In another aspect, the present disclosure provides a polynucleotide encoding a peptide described herein. In some embodiments, the polynucleotide is DNA or RNA. In some embodiments, the polynucleotide is single-stranded DNA or double-stranded DNA.

[0063] On the other hand, the present disclosure provides a vector comprising a polynucleotide disclosed herein. Typically, the vector further comprises additional elements that promote polypeptide expression, such as a promoter, an enhancer, a polyA region, etc. In some embodiments, the vector is a viral vector. In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the AAV vector further comprises an ITR sequence.

[0064] In another aspect, the present disclosure provides a recombinant virus comprising a polynucleotide disclosed herein. In some embodiments, the recombinant virus is AAV. In some embodiments, the AAV has a serotype selected from AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrh10, AAV11, and AAV12.

[0065] In another aspect, the present disclosure provides a host cell comprising a polynucleotide disclosed herein. The host cell can be used to express a peptide disclosed herein or to produce a virus disclosed herein.

[0066] On the other hand, the present disclosure provides a pharmaceutical composition comprising peptides, polynucleotides, vectors, recombinant viruses or host cells disclosed herein. Such compositions include peptides, polynucleotides, vectors, recombinant viruses or host cells and pharmaceutically acceptable carriers in a preventive or therapeutically effective amount. In a specific embodiment, the term "pharmaceutically acceptable" means approved by the regulatory agency of the federal government or state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeias for animals and more specifically for humans. Such pharmaceutical carriers can be sterile liquids, such as water and oil, including oils from petroleum, animals, plants or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, water is a specific carrier. Saline solutions and dextrose and glycerol aqueous solutions can also be used as liquid carriers, especially liquid carriers for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, ethylene glycol, water, ethanol and the like.

[0067] If necessary, the composition may also contain a small amount of wetting agent or emulsifier or pH buffer. These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, etc. Examples of suitable medicaments are described in Remington's Pharmaceutical Sciences. Such compositions will contain a preventive or therapeutically effective amount of polypeptides, polynucleotides, vectors, recombinant viruses or host cells together with an appropriate amount of carriers to provide a form of appropriate administration to the patient. The preparation should be suitable for administration, which may be intrathecal, intravenous, intraarterial, intrabuccal, intranasal, atomized, bronchial inhalation or delivered by mechanical ventilation. When the composition is administered by injection, an ampoule of sterile water for injection or saline may be provided so that the ingredients may be mixed before administration.

[0068] The compositions of the present disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include salts formed with anions, such as salts derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc., and salts formed with cations, such as salts derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.

[0069] How to use

[0070] On the other hand, the present disclosure provides a method for dissolving protein aggregates in cells. In some embodiments, the method includes introducing a peptide disclosed herein into the cell. In some embodiments, the cell is a neuron. In some embodiments, the protein aggregate is a FUS protein aggregate, a TDP-43 protein aggregate, a TIA1 protein aggregate, a β-amyloid protein aggregate, an α-synuclein aggregate, or a Huntington protein aggregate. In some embodiments, the polypeptide is introduced into the cell by contacting the cell with the peptide. In some embodiments, the peptide is introduced into the cell by introducing a polynucleotide encoding a peptide disclosed herein into the cell, thereby allowing the cell to express the peptide. In some embodiments, the polynucleotide is introduced into the cell by transforming or transfecting the cell with a vector or virus comprising the polynucleotide.

[0071] In yet another aspect, the present disclosure provides a method for treating a disease or condition associated with protein aggregation. In some embodiments, the disease or condition associated with protein aggregation is a neurodegenerative disease. Neurodegenerative diseases cause progressive structural or functional loss, and ultimately lead to cell death of neurons. Examples of neurodegenerative diseases include, but are not limited to, frontotemporal dementia, amyotrophic lateral sclerosis (ALS), cortical basal ganglionic degeneration, Lewy body dementia, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Parsons / dementia complex of the Kii Peninsula, progressive supranuclear palsy and Pick's disease.

[0072] Amyotrophic lateral sclerosis (ALS) involves degeneration of upper motor neurons (UMN) and lower motor neurons (LMN), with progressive symptoms of skeletal muscle weakness. Missense mutations in the gene encoding the antioxidant enzyme Cu / Zn superoxide dismutase 1 (SOD1) have been found in a subset of patients with familial ALS. However, the underlying pathogenic mechanisms of SOD1 mutant toxicity are not yet clear. TDP-43 and FUS protein aggregates have also been associated with some cases of the disease, and mutations in chromosome 9 (C9orf72) are considered the most common known cause of sporadic ALS.

[0073] Alzheimer's disease (AD) is a chronic neurodegenerative disease that causes the loss of neurons and synapses in the cerebral cortex and some subcortical structures, resulting in severe atrophy of the temporal lobe, parietal lobe, frontal cortex and cingulate gyrus. The main feature of AD pathology is the presence of senile plaques and neurofibrillary tangles. Plaques are composed of small peptides, usually 39-43 amino acids in length, known as beta-amyloid (also written as A-β or Aβ). Beta-amyloid is a fragment from a larger protein known as amyloid precursor protein (APP), which is a transmembrane protein that penetrates through the membrane of neurons. APP seems to play a role in normal neuronal growth, survival and post-injury repair. APP is cut into smaller fragments by enzymes such as gamma secretase and beta secretase. A fragment in these fragments produces the protofibrils of beta-amyloid, which can self-assemble into dense extracellular deposits, which are known as senile plaques or amyloid plaques.

[0074] Parkinson's disease (PD) is the second most common neurodegenerative disorder. The disease is usually manifested as bradykinesia, rigidity, resting tremor and postural instability. The main feature of PD is the death of dopaminergic neurons in the substantia nigra region of the midbrain. The cause of this selective cell death is unclear. It is worth noting that α-synuclein-ubiquitin complexes and aggregates are observed to accumulate in Lewy bodies in affected neurons. It is believed that defects in protein transport mechanisms and regulation, such as RAB1, may play a role in this disease mechanism. Impaired axonal transport of α-synuclein may also lead to its accumulation in Lewy bodies. Experiments show that wild-type and two familial Parkinson's disease-related mutant α-synuclein have reduced transport rates through cultured neuronal axons.

[0075] Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by mutations in the huntingtin gene (HTT). HD is characterized by loss of medium spiny neurons and astrogliosis. The first brain region to be substantially affected is the striatum, followed by degeneration of the frontal and temporal cortices. The subthalamic nucleus of the striatum sends control signals to the globus pallidus, which initiates and regulates movement. Therefore, weaker signals from the subthalamic nucleus reduce the initiation and regulation of movement, causing the characteristic movements of the disease, especially chorea. HD is caused by expansion of the polyglutamine tract in the huntingtin gene, resulting in mutant huntingtin. Aggregates of mutant huntingtin form as inclusions in neurons and can be directly toxic. In addition, these aggregates can damage molecular motors and microtubules to interfere with normal axonal transport, resulting in impaired transport of important substances such as BDNF.

[0076] In some embodiments, a method of treating a disease or condition associated with protein aggregation comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed herein.

[0077] The therapeutically effective amount of the pharmaceutical compositions provided herein will depend on various factors known in the art, such as the type of disease to be treated, body weight, age, past medical history, current medications, the subject's health status, immune status and the possibility of cross-reactions, allergies, sensitivities and adverse side effects as well as the route and type of administration, the severity and progression of the disease and the judgment of the attending physician or veterinarian. In certain embodiments, the pharmaceutical compositions provided herein can be administered at a therapeutically effective dose of about 0.001 mg / kg to about 100 mg / kg one or more times per day (e.g., about 0.001 mg / kg, about 0.3 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, or about 100 mg / kg administered one or more times per day). In some embodiments, the pharmaceutical composition is administered at a dosage of about 50 mg / kg or less, and in some embodiments, the dosage is 20 mg / kg or less, 10 mg / kg or less, 3 mg / kg or less, 1 mg / kg or less, 0.3 mg / kg or less, 0.1 mg / kg or less, or 0.01 mg / kg or less, or 0.001 mg / kg or less. In some embodiments, the dosage can be changed during treatment. For example, in some embodiments, the initial dosage can be higher than the subsequent dosage. In some embodiments, the dosage can change during treatment according to the reaction of the object.

[0078] The dosage regimen can be adjusted to provide the best desired response (e.g., therapeutic response). In certain embodiments, the pharmaceutical composition provided herein is administered to a subject once or in a series of treatments. In certain embodiments, the pharmaceutical composition provided herein is administered to a subject by one or more separate administrations or by continuous infusion according to the type and severity of the disease.

[0079] The pharmaceutical compositions provided herein can be administered by any route known in the art, e.g., parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, intradermal or intrathecal injection) or non-parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal or topical) routes.

[0080] In some embodiments, the pharmaceutical composition is applied to the central nervous system. In some embodiments, the pharmaceutical composition is applied by spinal injection, intrathecal injection, intraventricular injection, intracerebral injection or intrahippocampal injection. In some embodiments, the pharmaceutical composition provided herein is applied by intrathecal route. As used herein, the term "intrathecal administration", "intrathecal injection", "intrathecal delivery" or grammatical equivalent expression refers to injection into the spinal canal (the intrathecal space around the spinal cord). In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present disclosure refers to IT administration or delivery (that is, lumbar IT administration or delivery) or delivery in the cerebellomedullary cisterna magna by the opening between the skull and the top of the spine through the space around and below the cerebellum.

[0081] The following embodiments are provided to better illustrate the claimed invention, and should not be interpreted as limiting the scope of the present invention in any way. All specific compositions, materials and methods described below fall within the scope of the present invention in whole or in part. These specific compositions, materials and methods are not intended to limit the present invention, but only illustrate the specific embodiments falling within the scope of the present invention. Those skilled in the art can develop equivalent compositions, materials and methods without using inventive capabilities and without departing from the scope of the present invention. It should be understood that many changes can be made in the procedures described herein while still remaining within the scope of the present invention. It is the intention of the inventor of the present invention that such changes are all included within the scope of the present invention.

[0082] Table 1: Sequences mentioned in this application

[0083]

[0084]

[0085] Example 1

[0086] This example illustrates the analysis of charged amphiphilic (Champ) peptides capable of solubilizing protein aggregates.

[0087] The inventors have previously identified a Champ peptide (Champ-E) capable of dissolving protein aggregates, which is disclosed in PCT application PCT / CN2021 / 111683 and has an amino acid sequence of SEQ ID NO:1.

[0088] The inventors analyzed the percentages of different types of amino acid residues and the distribution of amino acid residues in Champ-E. The results of the analysis are shown in Figure 1 As shown in Figure 1 As shown, 41.5% of the amino acid residues in Champ-E are charged amino acid residues (E / D / R / K), 17.1% of the amino acid residues in Champ-E are hydrophobic amino acid residues (L / A / V / I / F / M / W), 29.3% of the amino acid residues in Champ-E are polar amino acid residues (H / S / Q / T / N / Y / C), and 12.2% of the amino acid residues in Champ-E are proline or glycine (P / G).

[0089] Given that charged amino acid residues have the highest percentage in Champ-E, the inventors first tested the function of charged amino acid residues in dissolving protein aggregates. The inventors generated a series of variants of Champ-E by mutation of aspartic acid residues and tested the ability of the variants to dissolve protein aggregates in vitro and in cells. The sequences of the variant peptides are Figure 2 The variant peptides were expressed in E. coli and then purified (see Figure 3 ). The purified variant peptides are then added to an in vitro protein solution that is capable of forming protein aggregates. The inventors have found that charged variant peptides (whether positively or negatively charged) are able to dissolve protein aggregates (see Figure 4 ). On the other hand, the uncharged "Champ"-Q variant peptide could no longer solubilize protein aggregates.

[0090] Since the charged amino acid residues in Champ-E are more concentrated at the N-terminus, and the NMR data during the solubilization of protein aggregates showed a relatively higher charge change at the N-terminus (results not shown), the inventors speculated that the amphipathic nature of the peptide may be important for solubilizing protein aggregates. The inventors used in vitro FDA (Fluorescein diacetate, which does not absorb light in an insoluble state but absorbs light at a wavelength of 488 nm in a soluble state) analysis to identify the amphipathicity of different short peptides and the solubility of FDA dyes. Figure 5 As shown, the results show that the charged short peptides Champ-E / Champ-D / Champ-K all have strong solubility, which is 100 times that of the positive control ATP, while the solubility of "Champ"-Q, which is mutated into polar amino acids and has no obvious depolymerization effect in vitro, is the worst. The results show that amphiphilicity is also required for depolymerization function.

[0091] Example 2

[0092] This example demonstrates the generation of Champ peptides that are capable of solubilizing protein aggregates.

[0093] Based on the known properties of Champ-E and short peptides that still have disaggregation after mutation to different charges, as well as the effect of in vitro amphipathic properties on disaggregation, the inventors screened the human proteome to identify 40 amino acid residue peptides (such peptides are fragments of naturally occurring human proteins) based on the following criteria: (a) at least 30% of the amino acid residues in the peptide are (i) charged amino acid residues selected from Asp and Glu or (ii) charged amino acid residues selected from Arg and Lys, wherein at least 80% of the charged amino acid residues are in the N-terminus or C-terminus of the peptide; (b) 14%-26% of the amino acid residues in the peptide are hydrophobic amino acid residues selected from Phe, Cys, Leu, Val and Ile; and (c) at least 10% of the amino acid residues in the peptide are polar amino acid residues selected from Ser, Asn, Thr, Gln, Tyr, Cys and His. A total of 13,543 peptide sequences were identified.

[0094] Then, the present inventors selected three peptides PLPR3 (SEQ ID NO: 6), ATXN8OS (SEQ ID NO: 7) and GRWD1 (SEQ ID NO: 8) to Figure 6 The experimental scheme shown here verifies the depolymerization function in eukaryotic cells. Figure 7-9 As shown, all three selected peptides had a depolymerizing effect.

[0095] To test the effect of proline / glycine residues in depolymerization, the inventors selected two peptides identified to have little or no P / G: TSYL2 (SEQ ID NO: 9) and C19L2 (SEQ ID NO: 10). Figure 10-11 As shown, both selected peptides had depolymerization, indicating that the P / G residues are not required for depolymerization.

[0096] To test the effect of polar residues (S / Q / T / N / Y / C / H) on depolymerization, the inventors selected two peptides that were identified to have few or no polar residues: ZNF326 (SEQ ID NO: 11) and CACNA1F (SEQ ID NO: 12). Figure 12-13 As shown, the two selected peptides showed little disaggregation, indicating that polar residues are required for disaggregation.

[0097] As shown in Example 1, when the charged amino acid residues in Champ-E are mutated to different charged amino acid residues, the variant peptide still has a depolymerization effect. To further test the effect of charged amino residues, especially when the variant peptide has a mixture of positively charged amino acid residues and negatively charged amino acid residues, the inventors mutated half of the 12 E residues in Champ-E to positively charged residues K to generate Champ6EK. Fig.14 As shown, Champ6EK still has a certain depolymerization effect.

[0098] The present inventors also selected the identified peptide CHD3 (SEQ ID NO: 13) which has a mixture of positively charged amino acid residues and negatively charged amino acid residues. CHD3 has charged residues enriched in the N-terminus, of which 30% are positively charged residues and 27.5% are negatively charged residues. Fig.15 As shown, CHD3 has a certain depolymerization effect.

[0099] The inventors then mutated the negatively charged residue E in CHD3 to a positively charged residue K to generate variant CHD3 (E2K) (SEQ ID NO: 14). Fig.16 As shown, CHD3(E2K) still has a certain depolymerization effect.

[0100] The present inventors further tested the peptide PELP1 (SEQ ID NO: 15) and found that the peptide PELP1 (SEQ ID NO: 15) was able to dissolve G3BP1 protein aggregates in vitro ( Fig.17 ).

[0101] While the invention has been particularly shown and described with reference to specific embodiments, some of which are preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as disclosed herein.

Claims

1. A method for producing a peptide capable of dissolving protein aggregates, the method comprising: Identification of naturally occurring proteins having a charged amphipathic (Champ) region of 40 to 100 amino acid residues, wherein (a) at least 30% of the amino acid residues in the Champ region are charged amino acid residues selected from Asp, Glu, Arg and Lys, wherein at least 80% of the charged amino acid residues are at the N-terminus or C-terminus of the Champ region, (b) 14% to 26% of the amino acid residues in the Champ region are hydrophobic amino acid residues selected from Phe, Cys, Leu, Val and Ile, and (c) at least 10% of the amino acid residues in the Champ region are polar amino acid residues selected from Ser, Asn, Thr, Gln, Tyr, Cys and His, and Peptides consisting of the Champ region were generated.

2. The method according to claim 1, further comprising: contacting the peptide with protein aggregates; as well as The peptide was determined to solubilize the protein aggregates.

3. The method of claim 1, further comprising mutating any of the charged amino acid residues in the peptide to a different charged amino acid residue.

4. The method of claim 1, wherein the peptide is selected from the group consisting of SEQ ID NOs: 1-15.

5. A peptide produced by the method according to any one of claims 1 to 4. A polynucleotide encoding the peptide according to claim 5. The polynucleotide according to claim 6 , which is DNA or RNA. A vector comprising the polynucleotide according to claim 6 or 7.

9. The vector according to claim 8, which is a viral vector.

10. The vector according to claim 9, which is an AAV vector. A recombinant virus comprising the polynucleotide according to claim 6 or 7.

12. The recombinant virus according to claim 11, which is AAV.

13. A host cell comprising the polynucleotide according to claim 6 or 7.

14. A pharmaceutical composition comprising: (1) a peptide according to claim 5, a polynucleotide according to claim 6 or 7, a vector according to any one of claims 8 to 10, a recombinant virus according to claim 11 or 12, or a host cell according to claim 13; and (2) a pharmaceutically acceptable carrier.

15. A method for solubilizing protein aggregates in cells, the method comprising introducing the peptide according to claim 5 into the cells.

16. The method of claim 15, wherein the cell is a neuronal cell.

17. The method of claim 15, wherein the cell is in vitro or in vivo.

18. A method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 14.

19. The method of claim 18, wherein the neurodegenerative disease is selected from the group consisting of frontotemporal dementia, amyotrophic lateral sclerosis, corticobasal ganglionic degeneration, dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Parkson's / dementia complex of Kii Peninsula, progressive supranuclear palsy, and Pick's disease.

20. The method of claim 19, wherein the pharmaceutical composition is administered to the central nervous system.

21. The method of claim 20, wherein the pharmaceutical composition is administered by spinal injection, intrathecal injection, intracerebroventricular injection, intracerebral injection, or intrahippocampal injection.

Citation Information

Patent Citations

  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and / or neurodegenerative diseases

    US10435373B2

  • Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

    US10889584B2

  • Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation

    US9284309B2

  • Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation

    US9527852B2

  • Heteroaryl amides as inhibitors of protein aggregation

    US9738635B2